Initial Decline in eGFR After Dapagliflozin Initiation and Its Associated Outcomes in Patients with HFrEF

In this post hoc analysis, the frequency of occurrence of an early decline ("dip") in estimated glomerular filtration rate (eGFR) after initiation of dapagliflozin, and its association with outcomes, was evaluated in heart failure patients participated in DAPA- HF trial. The mean change in eGFR between day 0 and 14 was -1.1 with placebo and -4.2 with dapagliflozin, giving a intergroup difference of 3.1. Overall, 38.2% of patients — with older age, lower baseline eGFR, higher LVEF, and type 2 diabetes — experienced a >10% early decline in eGFR with dapagliflozin compared with placebo (OR, 2.36). In the dapagliflozin group, a >10% initial decline in eGFR was associated with a 27% reduced risk of the primary outcome compared with those with a ≤10% decline (HR, 0.73). These findings highlight that an early decline in eGFR following dapagliflozin initiation is common, small, and associated with better clinical outcomes in HF patients with rEF. Disclaimer: Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any scientific information shared by the HCP on the ­­­STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this website.